Diabetic retinopathy mye1anagement

Marco A. Zarbin, William E Smiddy

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Strict control of blood glucose and blood pressure is critical for reduction of the incidence and progression of diabetic retinopathy (DR). Follow-up of patients with diabetes mellitus is protocol based and not based solely on the presence of symptoms. Staging of the level of DR (mild, moderate, or severe nonproliferative DR vs. proliferative DR, PDR) drives the follow-up interval. The most common cause of visual loss indiabetic patients is diabetic macular edema (DME). The results of multicenter, randomized studies suggest that the best visual results for DMEcurrently are achieved with intravitreal ranibizumab injections ± focal laser photocoagulation. Results using bevacizumab seem quite comparable to those with ranibizumab. In addition to treating DME, this approach also seems to reduce the likelihood of progression of DR. Selected patients also may benefit from intravitreal steroid treatment + focal laser therapy, but there is a relatively higher rate of glaucoma and cataract formation. Panretinal photocoagulation is currently the most effective treatment for high-risk PDR. Panretinal photocoagulation also should be considered for patients with severe nonproliferative DR and early PDR, particularly if followup cannot be assured and/or if the patient has type 2 diabetes mellitus. Pars plana vitrectomy is used to manage severe complications of DR such as nonclearing vitreous hemorrhage, severe fibrovascular proliferation, and retinal detachment. Adjunctive anti-vascular endothelial growth factor agents might enhance those results in selected subsets of patients.

Original languageEnglish (US)
Title of host publicationSurgical Retina
PublisherS. Karger AG
Pages1-34
Number of pages34
Volume2
ISBN (Print)9783318021592, 9783318021585
DOIs
StatePublished - Aug 15 2012

Fingerprint

Diabetic Retinopathy
Light Coagulation
Macular Edema
Vitreous Hemorrhage
Intravitreal Injections
Temazepam
Vitrectomy
Laser Therapy
Retinal Detachment
Glaucoma
Cataract
Type 2 Diabetes Mellitus
Vascular Endothelial Growth Factor A
Multicenter Studies
Blood Glucose
Diabetes Mellitus
Lasers
Steroids
Blood Pressure
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Zarbin, M. A., & Smiddy, W. E. (2012). Diabetic retinopathy mye1anagement. In Surgical Retina (Vol. 2, pp. 1-34). S. Karger AG. https://doi.org/10.4155/9783318021592.Ch1

Diabetic retinopathy mye1anagement. / Zarbin, Marco A.; Smiddy, William E.

Surgical Retina. Vol. 2 S. Karger AG, 2012. p. 1-34.

Research output: Chapter in Book/Report/Conference proceedingChapter

Zarbin, MA & Smiddy, WE 2012, Diabetic retinopathy mye1anagement. in Surgical Retina. vol. 2, S. Karger AG, pp. 1-34. https://doi.org/10.4155/9783318021592.Ch1
Zarbin MA, Smiddy WE. Diabetic retinopathy mye1anagement. In Surgical Retina. Vol. 2. S. Karger AG. 2012. p. 1-34 https://doi.org/10.4155/9783318021592.Ch1
Zarbin, Marco A. ; Smiddy, William E. / Diabetic retinopathy mye1anagement. Surgical Retina. Vol. 2 S. Karger AG, 2012. pp. 1-34
@inbook{b0643b1b39684ab79c1a64bb6bb47e73,
title = "Diabetic retinopathy mye1anagement",
abstract = "Strict control of blood glucose and blood pressure is critical for reduction of the incidence and progression of diabetic retinopathy (DR). Follow-up of patients with diabetes mellitus is protocol based and not based solely on the presence of symptoms. Staging of the level of DR (mild, moderate, or severe nonproliferative DR vs. proliferative DR, PDR) drives the follow-up interval. The most common cause of visual loss indiabetic patients is diabetic macular edema (DME). The results of multicenter, randomized studies suggest that the best visual results for DMEcurrently are achieved with intravitreal ranibizumab injections ± focal laser photocoagulation. Results using bevacizumab seem quite comparable to those with ranibizumab. In addition to treating DME, this approach also seems to reduce the likelihood of progression of DR. Selected patients also may benefit from intravitreal steroid treatment + focal laser therapy, but there is a relatively higher rate of glaucoma and cataract formation. Panretinal photocoagulation is currently the most effective treatment for high-risk PDR. Panretinal photocoagulation also should be considered for patients with severe nonproliferative DR and early PDR, particularly if followup cannot be assured and/or if the patient has type 2 diabetes mellitus. Pars plana vitrectomy is used to manage severe complications of DR such as nonclearing vitreous hemorrhage, severe fibrovascular proliferation, and retinal detachment. Adjunctive anti-vascular endothelial growth factor agents might enhance those results in selected subsets of patients.",
author = "Zarbin, {Marco A.} and Smiddy, {William E}",
year = "2012",
month = "8",
day = "15",
doi = "10.4155/9783318021592.Ch1",
language = "English (US)",
isbn = "9783318021592",
volume = "2",
pages = "1--34",
booktitle = "Surgical Retina",
publisher = "S. Karger AG",

}

TY - CHAP

T1 - Diabetic retinopathy mye1anagement

AU - Zarbin, Marco A.

AU - Smiddy, William E

PY - 2012/8/15

Y1 - 2012/8/15

N2 - Strict control of blood glucose and blood pressure is critical for reduction of the incidence and progression of diabetic retinopathy (DR). Follow-up of patients with diabetes mellitus is protocol based and not based solely on the presence of symptoms. Staging of the level of DR (mild, moderate, or severe nonproliferative DR vs. proliferative DR, PDR) drives the follow-up interval. The most common cause of visual loss indiabetic patients is diabetic macular edema (DME). The results of multicenter, randomized studies suggest that the best visual results for DMEcurrently are achieved with intravitreal ranibizumab injections ± focal laser photocoagulation. Results using bevacizumab seem quite comparable to those with ranibizumab. In addition to treating DME, this approach also seems to reduce the likelihood of progression of DR. Selected patients also may benefit from intravitreal steroid treatment + focal laser therapy, but there is a relatively higher rate of glaucoma and cataract formation. Panretinal photocoagulation is currently the most effective treatment for high-risk PDR. Panretinal photocoagulation also should be considered for patients with severe nonproliferative DR and early PDR, particularly if followup cannot be assured and/or if the patient has type 2 diabetes mellitus. Pars plana vitrectomy is used to manage severe complications of DR such as nonclearing vitreous hemorrhage, severe fibrovascular proliferation, and retinal detachment. Adjunctive anti-vascular endothelial growth factor agents might enhance those results in selected subsets of patients.

AB - Strict control of blood glucose and blood pressure is critical for reduction of the incidence and progression of diabetic retinopathy (DR). Follow-up of patients with diabetes mellitus is protocol based and not based solely on the presence of symptoms. Staging of the level of DR (mild, moderate, or severe nonproliferative DR vs. proliferative DR, PDR) drives the follow-up interval. The most common cause of visual loss indiabetic patients is diabetic macular edema (DME). The results of multicenter, randomized studies suggest that the best visual results for DMEcurrently are achieved with intravitreal ranibizumab injections ± focal laser photocoagulation. Results using bevacizumab seem quite comparable to those with ranibizumab. In addition to treating DME, this approach also seems to reduce the likelihood of progression of DR. Selected patients also may benefit from intravitreal steroid treatment + focal laser therapy, but there is a relatively higher rate of glaucoma and cataract formation. Panretinal photocoagulation is currently the most effective treatment for high-risk PDR. Panretinal photocoagulation also should be considered for patients with severe nonproliferative DR and early PDR, particularly if followup cannot be assured and/or if the patient has type 2 diabetes mellitus. Pars plana vitrectomy is used to manage severe complications of DR such as nonclearing vitreous hemorrhage, severe fibrovascular proliferation, and retinal detachment. Adjunctive anti-vascular endothelial growth factor agents might enhance those results in selected subsets of patients.

UR - http://www.scopus.com/inward/record.url?scp=84958107597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958107597&partnerID=8YFLogxK

U2 - 10.4155/9783318021592.Ch1

DO - 10.4155/9783318021592.Ch1

M3 - Chapter

SN - 9783318021592

SN - 9783318021585

VL - 2

SP - 1

EP - 34

BT - Surgical Retina

PB - S. Karger AG

ER -